Literature DB >> 11894840

Effect of geldanamycin on androgen receptor function and stability.

Donkena Krishna Vanaja1, Susan H Mitchell, David O Toft, Charles Y F Young.   

Abstract

In the ligand-binding inactive state, the steroid receptor heterocomplex contains Hsp90, Hsp70, high-molecular weight immunophilins, and other proteins. Hsp90 acts in association with co-chaperones to maintain the native state of the receptor within the cells. It was reported earlier that Hsp90 might not be as important for the androgen receptor (AR) activity as for the glucocorticoid receptor (GR) and the progesterone receptor (PR) activities. We used the Hsp90 inhibitor geldanamycin (GA) to explore the role of Hsp90 in the function of the AR heterocomplex. GA selectively binds to Hsp90 and inhibits its activity, leading to the loss of steroid receptor activity, and frequently, its degradation. In our study, LNCaP prostate cancer cells were treated with GA for 30 minutes or 24 hours, in the presence of mibolerone, a synthetic androgen. GA reduced the androgen-induced AR protein levels to 15% after 24 hours of treatment. Several androgen up-regulated genes, including immunophilin FKBP51 and prostate specific antigen (PSA), were reduced by GA treatment. In cells treated with GA after transfection with a PSA promoter or an androgen response element-driven reporter gene, AR-mediated transactivation of reporter gene expression was reversibly inhibited by GA. Loss of androgen-binding ability and AR levels was attributed to reduced transcription of AR-regulated gene expression. Degradation rate of 35S-labeled AR was significantly increased by GA in the presence or absence of mibolerone. GA induced the degradation of AR through the proteasomal pathway. AR in cells treated with proteasomal inhibitor lactacystin, was insoluble in Nonidet P-40 (NP40)-based buffer and could not restore the androgen-binding ability. We report here that GA treatment disrupted both hormone-binding activity and receptor protein stability, resulting in a dramatic loss of androgen-induced gene activation. These results show that Hsp90 activity is important for both the chaperone-mediated folding of the AR into a high-affinity ligand-binding conformation and the functional activity of the AR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11894840      PMCID: PMC514802          DOI: 10.1379/1466-1268(2002)007<0055:eogoar>2.0.co;2

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  52 in total

1.  An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene.

Authors:  S H Mitchell; P E Murtha; S Zhang; W Zhu; C Y Young
Journal:  Mol Cell Endocrinol       Date:  2000-10-25       Impact factor: 4.102

2.  Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.

Authors:  R Bagatell; O Khan; G Paine-Murrieta; C W Taylor; S Akinaga; L Whitesell
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

Review 3.  Steroid receptor interactions with heat shock protein and immunophilin chaperones.

Authors:  W B Pratt; D O Toft
Journal:  Endocr Rev       Date:  1997-06       Impact factor: 19.871

4.  Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells.

Authors:  B H Chung; S H Mitchell; J S Zhang; C Y Young
Journal:  Carcinogenesis       Date:  2001-08       Impact factor: 4.944

5.  A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.

Authors:  W Zhu; A Smith; C Y Young
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

6.  Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3eta.

Authors:  B Haendler; I Schüttke; W D Schleuning
Journal:  Mol Cell Endocrinol       Date:  2001-02-28       Impact factor: 4.102

7.  Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer.

Authors:  B K Ward; P J Mark; D M Ingram; R F Minchin; T Ratajczak
Journal:  Breast Cancer Res Treat       Date:  1999-12       Impact factor: 4.872

8.  Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding.

Authors:  W B Denny; D L Valentine; P D Reynolds; D F Smith; J G Scammell
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

9.  Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo.

Authors:  A T Bender; D R Demady; Y Osawa
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

10.  Mechanism of androgen-receptor augmentation. Analysis of receptor synthesis and degradation by the density-shift technique.

Authors:  A J Syms; J S Norris; W B Panko; R G Smith
Journal:  J Biol Chem       Date:  1985-01-10       Impact factor: 5.157

View more
  44 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

Review 3.  CYP17A1 inhibitors in castration-resistant prostate cancer.

Authors:  Lissette Gomez; Jason R Kovac; Dolores J Lamb
Journal:  Steroids       Date:  2015-01-03       Impact factor: 2.668

4.  Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.

Authors:  Shan Lu; Zongqin Tan; Matthew Wortman; Shan Lu; Zhongyun Dong
Journal:  Cancer Lett       Date:  2010-08-02       Impact factor: 8.679

Review 5.  FKBP51-a selective modulator of glucocorticoid and androgen sensitivity.

Authors:  Lance A Stechschulte; Edwin R Sanchez
Journal:  Curr Opin Pharmacol       Date:  2011-05-11       Impact factor: 5.547

6.  Berberine suppresses androgen receptor signaling in prostate cancer.

Authors:  Jing Li; Bo Cao; Xichun Liu; Xueqi Fu; Zhenggang Xiong; Li Chen; Oliver Sartor; Yan Dong; Haitao Zhang
Journal:  Mol Cancer Ther       Date:  2011-05-25       Impact factor: 6.261

7.  A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Authors:  Francois Lamoureux; Christian Thomas; Min-Jean Yin; Hidetoshi Kuruma; Ladan Fazli; Martin E Gleave; Amina Zoubeidi
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

8.  Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Authors:  Ayesha A Shafi; Marc B Cox; Nancy L Weigel
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

9.  Phenethyl isothiocyanate induces cell cycle arrest and reduction of alpha- and beta-tubulin isotypes in human prostate cancer cells.

Authors:  Ping Yin; Tomoya Kawamura; Meilan He; Donkena Krishna Vanaja; Charles Y F Young
Journal:  Cell Biol Int       Date:  2008-10-11       Impact factor: 3.612

10.  20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.

Authors:  Bo Cao; Xichun Liu; Jing Li; Shuang Liu; Yanfeng Qi; Zhenggang Xiong; Allen Zhang; Thomas Wiese; Xueqi Fu; Jingkai Gu; Paul S Rennie; Oliver Sartor; Benjamin R Lee; Clement Ip; Lijuan Zhao; Haitao Zhang; Yan Dong
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.